Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regen BioPharma (RGBP) EBITDA (2016 - 2025)

Historic EBITDA for Regen BioPharma (RGBP) over the last 13 years, with Q3 2025 value amounting to -$123055.0.

  • Regen BioPharma's EBITDA fell 4408.91% to -$123055.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$338538.0, marking a year-over-year increase of 1885.88%. This contributed to the annual value of -$338540.0 for FY2025, which is 1885.84% up from last year.
  • According to the latest figures from Q3 2025, Regen BioPharma's EBITDA is -$123055.0, which was down 4408.91% from -$40756.0 recorded in Q2 2025.
  • Regen BioPharma's 5-year EBITDA high stood at -$12973.0 for Q1 2021, and its period low was -$463867.0 during Q4 2022.
  • For the 5-year period, Regen BioPharma's EBITDA averaged around -$103400.3, with its median value being -$85402.0 (2024).
  • In the last 5 years, Regen BioPharma's EBITDA tumbled by 57071.76% in 2021 and then soared by 7353.08% in 2023.
  • Quarter analysis of 5 years shows Regen BioPharma's EBITDA stood at -$106422.0 in 2021, then tumbled by 335.88% to -$463867.0 in 2022, then soared by 73.53% to -$122782.0 in 2023, then soared by 50.01% to -$61378.0 in 2024, then tumbled by 100.49% to -$123055.0 in 2025.
  • Its EBITDA stands at -$123055.0 for Q3 2025, versus -$40756.0 for Q2 2025 and -$113349.0 for Q1 2025.